{
    "cancelStatus": "1",
    "cancelDate": "2023-06-02",
    "cancelReason": [
        "856"
    ],
    "licid": "52027066",
    "validDate": "2022-02-22 00:00:00.000",
    "issueDate": "2017-02-22 00:00:00.000",
    "licKind": "02",
    "oldLicid": null,
    "certNo": "DHA05202706601",
    "prodNameC": "\"卡比\"倍莫舒癌注射劑100毫克",
    "prodNameE": "Pemetrexed\"Kabi\" for Injection 100mg\/vial",
    "indicationsName": [
        "1.併用cisplatin是治療局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）之第一線化療用藥。2.Pemetrexed單一藥物是局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）病人接受4個週期含鉑藥物的第一線化療後疾病並未惡化之維持療法。3.單一藥物是治療局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）之第二線治療用藥。4.與cisplatin併用於治療惡性肋膜間質細胞瘤。"
    ],
    "does": "2243",
    "packageUnit": [
        {
            "packageSpec": "100毫克",
            "packageUnit": "L2"
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": null,
    "ingredientsDesc": [
        "PEMETREXED DISODIUM HEPTAHYDRATE"
    ],
    "restraintItemsCode": [
        "02",
        "24"
    ],
    "applicantName": "台灣費森尤斯卡比股份有限公司",
    "applicantAddr": "台北市大安區仁愛路三段30號5樓32號5樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": null,
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "factoryCode": "1",
            "factoryName": "FRESENIUS KABI ONCOLOGY LIMITED",
            "factoryAddr": "VILLAGE-KISHANPURA, P.O. GURU MAJRA, TEHSIL-NALAGARH, DISTT. SOLAN, (H.P.)-174101, INDIA",
            "factoryCompanyAddr": null,
            "countryCode": "IN",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FIN0368000",
            "factoryInfo": null,
            "qsd": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1004002410",
            "ingredientsDesc": "PEMETREXED DISODIUM HEPTAHYDRATE",
            "concentDesc": "Pemetrexed (as Pemetrexed Disodium) (Pemetrexed Disodium is formed in situ from Pemetrexed Diacid)",
            "concent": "100.000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [
        {
            "licChgDocId": "4AD6D6F6-DA9E-4E98-B6E9-754BD0EE3B61",
            "approvedDocNo": "1096807544",
            "approvedDate": "2020-11-06",
            "changeItem": null,
            "changeRecord": null,
            "remark": ""
        }
    ],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01BA04"
        }
    ]
}